Skip to main content

Diabetes

  • Novo Nordisk, Children with Diabetes team up to educate newly diagnosed Type 1 diabetics

    ORLANDO, Fla. — Danish drug maker Novo Nordisk will work with advocacy group Children with Diabetes to distribute materials to children newly diagnosed with Type 1 diabetes, the two said Thursday.

    The approximately 7,000 kits, designed to help them learn to live with the condition, include a booklet, savings offers and patient-support videos, and were created based on feedback from CWD members with Type 1 diabetes. Patients can order the kits through their doctors.

  • Decision Resources: Victoza may outpace Byetta

    BURLINGTON, Mass. — Novo Nordisk could be outpacing Eli Lilly and Amylin Pharmaceuticals in the diabetes wars, according to an analysis by healthcare market research firm Decision Resources.

  • Lobbying groups urge Congress to keep diabetes testing supplies accessible to patients

    ALEXANDRIA, Va. — Pharmacy groups are urging Congress to maintain access to diabetic testing supplies in retail pharmacies for patients with diabetes.

  • Diabetics cite fatigue as daily challenge

    BOCA RATON, Fla. — As many as 85% of people with diabetes identified fatigue as one of their leading daily challenges, according to a recent survey of 8,000 diabetics commissioned by Diabetica Research Solutions.

    Only 6% of survey respondents noted, however, that they use energy drinks.

  • MannKind: Patients have better view of insulin therapy when using Afrezza

    SAN DIEGO — Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

    MannKind said that patients taking the investigational inhaled insulin Afrezza (insulin human [rDNA origin]) with basal insulin came to view insulin therapy more positively during the 16-week study than those taking Eli Lilly’s injected Humalog (insulin lispro [rDNA origin]) with basal insulin.

  • Incorporating nuts into diet may help diabetics with blood-sugar control, cholesterol

    FRESNO, Calif. — Consuming nuts in place of carbohydrates may help improve long-term blood-sugar control and lower cholesterol levels among Type 2 diabetics, according to a new study.

  • Exenatide improves glucose control among diabetes patients in mid-stage trial

    SAN DIEGO — A once-monthly formulation of a drug made by Amylin Pharmaceuticals, Eli Lilly and Alkermes improved glucose control in patients with Type 2 diabetes, according to results of a mid-stage clinical trial presented at the American Diabetes Association’s 71st Scientific Sessions.

    The three companies said once-monthly injections of the drug exenatide improved blood-sugar control and produced modest weight loss in the 121-patient phase-2 study.

  • Study finds that low body fat may not reduce risk of diabetes, heart disease

    BOSTON — People with lower percentages of body fat are not necessarily at lower risk for diabetes and heart disease, according to a new international study.

    The study identified a gene that is linked with having less body fat but also with having an increased risk of Type 2 diabetes and heart disease. The investigators examined the genomes of more than 75,000 people and found that the gene, IRS1, was linked to less body fat, but also to unhealthy levels of cholesterol and blood glucose.

X
This ad will auto-close in 10 seconds